LSV Asset Management Decreases Stake in Henry Schein, Inc. (NASDAQ:HSIC)

LSV Asset Management lowered its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 96.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,400 shares of the company’s stock after selling 57,100 shares during the quarter. LSV Asset Management’s holdings in Henry Schein were worth $166,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Smartleaf Asset Management LLC lifted its holdings in shares of Henry Schein by 23.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock worth $52,000 after acquiring an additional 143 shares during the last quarter. CIBC Asset Management Inc boosted its position in shares of Henry Schein by 1.0% during the 4th quarter. CIBC Asset Management Inc now owns 17,849 shares of the company’s stock worth $1,235,000 after acquiring an additional 169 shares in the last quarter. Metis Global Partners LLC boosted its holdings in Henry Schein by 4.7% in the fourth quarter. Metis Global Partners LLC now owns 4,203 shares of the company’s stock valued at $291,000 after purchasing an additional 187 shares in the last quarter. Central Pacific Bank Trust Division grew its position in shares of Henry Schein by 2.0% in the 4th quarter. Central Pacific Bank Trust Division now owns 10,200 shares of the company’s stock valued at $706,000 after buying an additional 200 shares during the last quarter. Finally, Sanctuary Advisors LLC grew its holdings in shares of Henry Schein by 5.0% during the fourth quarter. Sanctuary Advisors LLC now owns 4,253 shares of the company’s stock worth $294,000 after purchasing an additional 203 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Stock Performance

Shares of NASDAQ HSIC opened at $64.28 on Wednesday. Henry Schein, Inc. has a 1 year low of $60.49 and a 1 year high of $82.49. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The firm has a market cap of $7.98 billion, a P/E ratio of 26.45, a PEG ratio of 2.13 and a beta of 0.84. The stock has a fifty day moving average price of $71.27 and a two-hundred day moving average price of $72.13.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing the consensus estimate of $1.23 by ($0.04). The firm had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.66 EPS. Research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insider Activity

In other Henry Schein news, Director Philip A. Laskawy sold 2,604 shares of the business’s stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the sale, the director now owns 24,805 shares of the company’s stock, valued at $1,762,147.20. The trade was a 9.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the transaction, the chief executive officer now directly owns 62,688 shares of the company’s stock, valued at approximately $4,460,251.20. The trade was a 6.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

Analysts Set New Price Targets

HSIC has been the topic of a number of recent research reports. StockNews.com upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Wednesday, April 9th. UBS Group cut their price objective on Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a research report on Wednesday, February 26th. Barrington Research reiterated an “outperform” rating and set a $90.00 price target on shares of Henry Schein in a research report on Wednesday, February 26th. Bank of America upgraded shares of Henry Schein from an “underperform” rating to a “buy” rating and boosted their price objective for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. Finally, Jefferies Financial Group upped their target price on Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Five research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Henry Schein has an average rating of “Moderate Buy” and an average target price of $81.10.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.